IE 11 is not supported. For an optimal experience visit our site on another browser.

Spectrum Pharmaceuticals, Inc. (SPPI) Chairman, CEO and President to Ring the NASDAQ Stock Market Opening Bell

ADVISORY, Sept. 27, 2010 (GLOBE NEWSWIRE) --
/ Source: GlobeNewswire

ADVISORY, Sept. 27, 2010 (GLOBE NEWSWIRE) --

What:

Rajesh C. Shrotriya, MD, Chairman of the Board, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. (SPPI) will visit NASDAQ MarketSite in Times Square and preside over the NASDAQ Opening Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Tuesday, September 28, 2010 at 9:15 a.m. to 9:30 a.m. ET     

Contacts:

Paul Arndt
949-743-9216
paul.arndt@sppirx.com

NASDAQ MarketSite:
Jolene Libretto
(646) 441-5220
Jolene.Libretto@NASDAQOMX.com

Feed Information:

The Opening Bell is available from 9:20 a.m. to 9:35 a.m. on AMC3/C22 87 degrees West DL freq.: 4140 vertical. The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.

Radio Feed:

An audio transmission of the Opening Bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

For news tweets, please visit our Twitter page at:

Webcast:

A live webcast of the NASDAQ Opening Bell will be available at:

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Spectrum Pharmaceuticals, Inc. [SPPI]:

Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The Company's strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products.  The Company markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates.  The Company has assembled an integrated in-house scientific team, including clinical development, medical research, regulatory affairs, biostatistics and data management, formulation development, and has established a commercial infrastructure for the marketing of its drug products.  The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy.  For more information, please visit the Company's website at

About NASDAQ OMX:

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,600 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries.  NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit . *Please follow NASDAQ OMX on Facebook () and Twitter ().

NDAQA